1. Steady growth in performance:
The company's revenue increased 7.9% to 915.12 million yuan. The profit attributable to the company's equity shareholders increased by 37.0% to RMB 131.85 million, of which the net profit increased rapidly in the second half of the year, with a net profit of 80 million yuan. Through the rapid growth of its own products, the company has achieved steady growth in revenue.
2. Xidi Ke
Xidi Ke is commonly known as uric acid peptide injection, which is independently produced by Jiangsu Biopharmaceutical. Xidi Ke is the only drug to treat myelodysplastic syndrome (MDS). Xidi Ke can also be used in the treatment of advanced breast cancer and non-small cell lung cancer. The product has been certified for class 1.1 new drugs. At present, the new plant has passed the GMP inspection and is allowed to go on the market. It will be sold in hospitals in April, with a target of selling 220000 bottles in 2017, with a total sales volume of more than 100 million yuan and a gross profit margin of more than 80%. The net profit margin is expected to reach 20%.
3. Shu Si:
Shusi is commonly known as quetiapine fumarate tablets. Shusi's revenue rose 48 per cent to 210 million yuan, with a gross profit margin of 75 per cent. The increase in Shuth sales is due to the increasingly favorable market environment and improved inventory management in distribution channels. Shusi is suitable for the treatment of schizophrenia and manic episodes of bipolar disorder. The incidence of mental illness in China is high and on the rise, so the growth space of this product is worth looking forward to. At present, there are only three manufacturers in China, and Shusi accounts for 35%. Target sales of 8 million boxes in 2017. Growth is expected to accelerate as health care restrictions are lifted.
4. Secret cover information:
On May 18, 2016, the company entered into a number of agreements with Novartis to acquire secret interest-capping drugs, mainly for the treatment of osteoporosis. The price is about 900 million RMB. At present, sales in China account for 80%, with sales of more than 200 million. The gross profit margin of this product is 80%, and the profit margin can reach 30-40%. Through Tailing's channels, sales are expected to grow rapidly. The current market share is 40%, and it is expected to reach 50% in the future.
5. Li Baoduo:
The income of Libaoduo, a tumor drug made in Zhangjiang, Fudan, increased by 2.5% to 555 million yuan.
Sales of 90,000 units, with a target of 100,000 units in 2017.
6. Pine Gardenia Pill:
It is a new national drug and the only traditional Chinese medicine to treat hepatitis C. it has a unique effect on fatty liver. It sold 108000 boxes in the second half of 2016 and aims to sell 210,000 boxes this year, with an income of more than 55 million yuan.
7. Zhuo ao:
Zhuo ao's income has declined. The decrease in Zhuo's sales is mainly due to the restructuring of its single distributor Sihuan Pharmaceutical during the period, thus affecting product sales performance. After the adjustment was completed, sales improved in the second half of 2016.
8. Summary and suggestions:
The company has completed gorgeous transformation, its own varieties Shu Si, Xidi Ke are seriously ill varieties, especially Xidi Ke is the only drug for the treatment of MDS, the growth space can be expected, close cover interest is a high gross profit rate, market-based products, the company is expected to achieve rapid growth in performance this year, can be actively concerned.
